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Abstract
Purpose: To investigate the impact of interfractional anatomical changes and setup
correction methods on dose distributions in pancreatic cancer patients under
breath‐hold conditions.
Methods: Three intensity‐modulated proton therapy (IMPT) plans with different
beam arrangements and one volumetric‐modulated arc therapy (VMAT) plan pre-
scribing 54 Gy in 30 fractions were created for 10 patients who underwent three
additional CT scans performed at an interval of 1–2 weeks. The additional CT sets
were rigidly registered to the simulation CT set using both bone‐matching (BM) and
organ‐matching (OM) methods in each patient. Recalculated dose distributions and
dose–volume indices on the additional CT sets using either the BM or the OM
method were compared with the simulation values.
Results: Differences in the gross tumor volume D98% value from the simulation sets
ranged from −0.8 to −5.9% on average. In addition, the variations were larger with
OM compared with BM for two IMPT plans. Meanwhile, differences in the D98%
value in the region isotropically enlarged by 5 mm from the gross tumor volume
were significantly improved with OM on two IMPT plans and the VMAT plan.
Among the organs at risk, the dose–volume indices were significantly improved with
OM only in the duodenum on all plans.
Conclusion: Organ‐matching may be a better setup correction technique than BM
for both photon therapy and IMPT plans. However, in some beam arrangements of
IMPT, the dose distribution may be somewhat worse using OM, due to interfrac-
tional anatomical variation. Therefore, it is important to choose beam angles that
are less likely to be influenced by changes in the gastrointestinal gas volume, espe-
cially in IMPT plans.
K E Y WORD S
bone‐matching vs organ‐matching, IMPT, interfractional anatomical variation, VMAT, pancreatic
cancer
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1 | INTRODUCTION
Pancreatic cancer is one of the most common causes of cancer‐
related mortality.1 Although the most promising treatment method
for long‐term survival of pancreatic cancer patients is surgical
resection, at diagnosis most patients present with inoperable dis-
ease, such as locally advanced or metastatic disease; therefore,
radiotherapy is considered an important treatment modality, par-
ticularly for patients with locally advanced pancreatic cancer
(LAPC).2
There are some difficulties associated with treating LAPC
patients with radiotherapy. Anatomical positioning causes a signifi-
cant challenge, as the pancreas is surrounded by radiosensitive
organs at risk (OARs) such as the stomach and duodenum. This
makes it difficult to deliver high doses to the tumor without increas-
ing the radiation dose to OARs. Intensity‐modulated radiotherapy
(IMRT), volumetric modulated arc therapy (VMAT), and particle ther-
apy have been effective in reducing the dose to surrounding OARs
in simulation.3–5 However, as several investigators have mentioned,
there are issues with position repeatability when treating the pan-
creas, due to intrafractional body movements, respiratory motion,
and variations in gastrointestinal contents.6,7 The positional uncer-
tainty results in a decreased target coverage and increased dose to
OARs. To reduce these uncertainties, immobilization devices, respira-
tory motion management, and fasting before radiotherapy have been
commonly employed.8,9
Among the setup correction methods used before beam deliv-
ery are bone‐matching (BM) and organ‐matching (OM) methods.
With respect to the setup correction method, it has been suggested
that marker‐matching and OM are far superior to skin‐marking‐
matching methods and superior even to BM in photon therapy.10
Likewise, in carbon ion therapy (CIRT), OM and marker‐matching
are reportedly superior to BM for the lung and liver.11,12 Mean-
while, in CIRT for pancreatic cancer, a small effect of the setup cor-
rection method on dose distribution was demonstrated13; this is
because the dose distribution in particle therapy, compared with
photon therapy, is easily distorted by interfractional anatomical
variations such as changes in physique and gastrointestinal gas in
abdominal therapy.14
The interfractional dose variations due to differences in setup
correction methods in CIRT were assessed in previous studies.11–13
However, there is insufficient literature on quantitative evaluation of
the dose variations among setup correction methods in proton beam
therapy (PBT). Furthermore, the interfractional dose variation of dif-
ferent radiotherapy modalities using different setup correction meth-
ods has not been investigated previously in pancreatic cancer
patients.
The purpose of this study was to investigate the impact of inter-
fractional anatomical variation and setup correction methods, and
specifically OM (i.e., cone‐beam CT [CBCT] matching) and BM (i.e.,
orthogonal kV x‐ray imaging matching), on the dose distributions in
pancreatic cancer patients under end‐exhalation breath‐hold (EBH)
conditions.
2 | MATERIALS AND METHODS
This study was conducted in accordance with the Declaration of
Helsinki and was approved by our Institutional Ethical Review Board
(approval number R1446).
2.A | Patients and CT scans
Data from 10 consecutive LAPC patients treated with chemoradio-
therapy at our institution between January 2009 and August 2009
were used in this study. All patients had undergone three additional
CT scans, performed at an interval of 1–2 weeks during a chemora-
diotherapy course and under the same conditions as in the simula-
tion CT scan. The characteristics of the patients are shown in
Table 1.
CT was performed under EBH condition using the LightSpeed RT
scanner (GE Healthcare, Little Chalfont, UK) and Real‐time Position
Management system (RPM; Varian Medical Systems, Palo Alto, CA).
The CT slice thickness was 2.5 mm. Patients fasted for at least 3 h
and were immobilized in the supine position with both arms raised
in a BodyFIX vacuum cushion (Elekta, Stockholm, Sweden).
2.B | Target volume and OAR delineation
The gross tumor volume (GTV) included the primary tumor and
metastatic lymph nodes. The clinical target volume (CTV) was
defined as the GTV plus a 5 mm margin in each direction (GTV+5
mm) combined with the retropancreatic and para‐aortic space
between the 10 mm superior of the celiac axis and the 10 mm
inferior of the superior mesenteric artery. The planning target vol-
ume (PTV) was defined by adding a 5 mm margin to the CTV.5,15–
17 The same PTV was used in the intensity‐modulated proton ther-
apy (IMPT) and volumetric‐modulated arc therapy (VMAT) plans,
based on previous studies in which 5 mm PTV margins were used
even in IMPT and CIRT plans.5,16,17 In addition, using the same
TAB L E 1 Patient characteristics.
Pt. no. Sex Age (yr) Location TNM
1 F 76 Body T4N0M0
2 F 72 Body T4N0M0
3 M 44 Body T4N1M0
4 M 72 Body T4N0M0
5 M 66 Head T4N0M0
6 M 58 Head T3N0M1 (LYM*)
7 M 66 Body T4N0M0
8 M 66 Head T4N0M0
9 M 66 Head T4N0M0
10 M 46 Body T4N0M0
Note: Pt. no., patient number; M, male; F, female; location, location of
the tumor in the pancreas; TNM, stage according to the International
Union Against Cancer classification 7th edition; *, distant lymph node
within the irradiation field.
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structures yielded equivalent plans for IMPT and VMAT. The GTV,
GTV+5 mm, stomach, duodenum, and small intestine were delin-
eated on all 40 CT sets (10 simulation and 30 additional CT sets)
and CTV, PTV, spinal cord, liver, and kidney were delineated on 10
simulation CT sets by one radiation oncologist and reviewed by
two experts.
2.C | Treatment planning
We constructed three different IMPT plans and one VMAT plan
prescribing 54 Gy in 30 fractions for each patient on the Eclipse
treatment planning system, version 15.6 (Varian Medical Systems)
for the purpose of this study. In the IMPT plans, we used a spot‐
F I G . 2 . Differences in the dose–volume
indices (DVIs) of the target volumes
between the simulation plans and the
assigned plans. The horizontal and vertical
axes show the DVIs for the simulation
plans and assigned plans, respectively. The
four symbol shapes show the plan type
(circle: RP plan, square: RPOL plan,
rhombus: ORPOL plan, triangle: volumetric‐
modulated arc therapy plan), and the 10
colors indicate the 10 patients (empty:
with bone‐matching, filled: with organ‐
matching). The chain line is the line at
which the DVI on the simulation plans
versus the assigned plans is the same.
F I G . 1 . Field setup and dose deposition.
(a) Proton plan with right and posterior
beams (RP plan), (b) proton plan with right,
posterior and left posterior oblique beams
(RPOL plan), (c) proton plan with right
posterior oblique, posterior and left
posterior oblique beams (ORPOL plan), (d)
photon plan (volumetric‐modulated arc
therapy plan).
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scanning technique with two or three incident proton beams of
kinetic energies between 70 and 250 MeV delivered by the Varian
proton therapy system. Three different IMPT plans were used: (a)
gantry angles of 180° and 270° (right and posterior [RP] plan); (b)
gantry angles of 135°, 180°, and 270° (right, posterior, and left
posterior oblique [RPOL] plan); (c) gantry angles of 135°, 180°,
and 225° (right posterior oblique, posterior, and left posterior obli-
que [ORPOL] plan). Since a previous study showed that the dose
distributions from the anterior and left directions may be over-
shot/undershot,18 the combination of right and posterior directions
has since become a commonly used beam angle in two‐field IMPT
planning.19 The RPOL plan was designed to add a third beam
F I G . 3 . Differences in the dose–volume indices (DVIs) of organs at risk between the simulation plans and the assigned plans. The horizontal
and vertical axes show the dose–volume indices for the simulation plans and assigned plans, respectively. The four symbol shapes indicate the
plan type (circle: RP plan, square: RPOL plan, rhombus: ORPOL plan, triangle: volumetric‐modulated arc therapy plan), and the 10 colors the 10
patients (empty: with bone‐matching, filled: with organ‐matching). The chain line shows the dose–volume constraints in the simulation.
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path other than anterior and left directions to the RP plan. The
beam angles of the ORPOL plan are also commonly used in IMPT
plans in three‐field IMPT planning.19,20 The advantage is a reduc-
tion of the volume delivered to the descending part of the duode-
num via the beam path. The VMAT plan consisted of one
coplanar full‐arc of 10 MV flattening filter‐free photon beams that
rotated clockwise from 181° to 179° using the TrueBeam STx
with a high‐definition 120‐leaf multileaf collimator (Varian Medical
Systems). The dose calculation algorithms used were the analytical
proton convolution superposition algorithm for the IMPT plans
and Acuros XB (Varian Medical Systems) for the VMAT plan. The
CT numbers of gastrointestinal gas were not overridden to those
TAB L E 2 Differences in dose–volume indices (mean ± 2 SD) between the simulation and assigned plans.
RP RPOL ORPOL VMAT
BM − Sim OM − Sim BM − Sim OM − Sim BM − Sim OM − Sim BM − Sim OM − Sim
GTV
D50% [%] ‐0.9 ± 1.7 ‐0.8 ± 1.9* ‐0.7 ± 1.4 ‐0.7 ± 1.5 ‐0.3 ± 0.6 ‐0.2 ± 0.5 ‐0.6 ± 3.3 ‐0.6 ± 3.2
D98% [%] ‐5.2 ± 17.8 ‐5.9 ± 21.1 ‐3.7 ± 12.6 ‐3.9 ± 14.5 ‐1.7 ± 7.5 ‐1.0 ± 4.0 ‐1.2 ± 3.6 ‐0.8 ± 2.7*
GTV + 5 mm
D50% [%] ‐0.5 ± 1.7 ‐0.4 ± 1.5 ‐0.3 ± 1.4 ‐0.3 ± 1.4 0.0 ± 0.6 0.0 ± 0.5* ‐0.5 ± 3.4 ‐0.5 ± 3.1
D98% [%] ‐9.2 ± 26.8 ‐7.9 ± 25.9 ‐7.1 ± 25.0 ‐5.4 ± 21.0* ‐5.5 ± 23.6 ‐2.1 ± 12.1* ‐3.1 ± 13.3 ‐1.0 ± 4.2*
Stomach
V45Gy [cm
3] 0.0 ± 5.9 ‐0.4 ± 4.8 0.2 ± 6.2 ‐0.1 ± 4.7 0.4 ± 6.3 0.1 ± 5.0 2.9 ± 13.6 1.8 ± 7.0
V48Gy [cm
3] 0.0 ± 4.8 ‐0.4 ± 3.8 0.2 ± 5.1 ‐0.2 ± 3.7 0.4 ± 5.4 0.1 ± 4.1 2.3 ± 11.0 1.3 ± 5.5
V52Gy [cm
3] 0.4 ± 2.5 0.1 ± 1.9 0.5 ± 2.6 0.1 ± 1.9 0.7 ± 3.0 0.4 ± 2.1 1.3 ± 5.1 0.7 ± 2.3
Duodenum
V45Gy [cm
3] 0.2 ± 4.7 ‐0.5 ± 3.7** 0.3 ± 4.5 ‐0.3 ± 3.6** 0.4 ± 4.1 ‐0.3 ± 3.4** 0.5 ± 4.6 ‐0.3 ± 3.9**
V48Gy [cm
3] 0.2 ± 3.9 ‐0.3 ± 2.9** 0.3 ± 3.7 ‐0.2 ± 2.9** 0.4 ± 3.5 ‐0.2 ± 2.8** 0.5 ± 3.7 ‐0.2 ± 2.9**
V52Gy [cm
3] 0.2 ± 1.8 ‐0.1 ± 1.1** 0.5 ± 2.0 0.1 ± 1.2** 0.4 ± 2.2 0.1 ± 1.6** 0.4 ± 2.0 0.1 ± 1.4**
Small intestine
V45Gy [cm
3] ‐1.4 ± 6.1 ‐1.2 ± 5.1 ‐1.1 ± 5.1 ‐0.9 ± 4.0 ‐1.1 ± 5.1 ‐0.8 ± 3.7 ‐0.5 ± 5.9 ‐0.2 ± 4.1
V48Gy [cm
3] ‐0.8 ± 3.4 ‐0.7 ± 3.0 ‐0.7 ± 3.3 ‐0.6 ± 2.8 ‐0.6 ± 3.1 ‐0.5 ± 2.3 ‐0.2 ± 3.5 ‐0.1 ± 2.4
V52Gy [cm
3] 0.4 ± 2.2 0.4 ± 1.9 0.4 ± 1.8 0.3 ± 1.6 0.3 ± 1.6 0.2 ± 1.2 0.4 ± 2.0 0.3 ± 1.4
Abbreviations: BM – Sim, difference between the simulation plans and plans assigned using bone‐matching; GTV, the gross tumor volume, GTV + 5 mm,
the volume after adding a 5 mm margin in all directions to the GTV, DX%, the dose to X% of the target volume; OM – Sim, difference between the sim-
ulation plans and plans assigned using organ‐matching; ORPOL, proton plans with right posterior oblique, posterior and left posterior oblique beams,
VMAT, volumetric‐modulated arc therapy; RP, proton plans with right and posterior beams; RPOL, proton plans with right, posterior and left posterior
oblique beams; SD, standard deviation; VXGy, the volume receiving X Gy.
*p < 0.05, paired t‐test.
**p < 0.01, paired t‐test.
F I G . 4 . Differences in the water equivalent path length (WEPL) with bone matching (BM) and organ matching (OM). The boxplots show the
differences from simulation plans in the WEPL at isocenter among each gantry angle (a) with BM, and (b) with OM.
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of the surrounding tissue in this study. Figure 1 illustrates the
field setup and dose distribution.
The prescribed dose of 54 Gy was the dose to 50% of the PTV
(D50%: DX% is the dose delivered to X% of the target volume). The
maximum dose should be <60 Gy. Regarding the OARs, the V45Gy
(VXGy is the volume receiving X Gy), V48Gy, and V52Gy of the stomach,
duodenum, and small intestine were limited to <20, 5, and 1 cm3,
respectively. Although a PTV D95% ≥ 95% was the goal (no devia-
tion), if this was difficult to achieve within the constraints of the gas-
trointestinal tract, the PTV was reduced to D95% ≥ 90% (minor
deviation). The constraints of OARs other than the gastrointestinal
tract were as follows: maximum dose to the spinal cord <45 Gy and
to each kidney V18Gy < 30%, and mean dose to the liver < 25 Gy.
2.D | Analysis of interfractional dose variation
The additional CT sets were rigidly registered to the simulation CT
sets using both BM and OM, and the target volumes and OARs were
again delineated on the additional CT sets. OM was conducted by a
single board‐certified radiation oncologist using three‐dimensional
translation without rotation. Then, the plans on the simulation CT
sets were assigned to the additional CT sets and recalculated in the
BM and OM settings without overriding the CT numbers of gastroin-
testinal gas to evaluate the interfractional dose variations, respec-
tively (assigned plan). To evaluate the dose coverage, the D50% and
D98% of the GTV and GTV+5 mm in the assigned plans were evalu-
ated. For the OARs, the V45Gy, V48Gy, and V52Gy of the stomach,
duodenum, and small intestine were evaluated, respectively.
All statistical analyses were performed using R (version 3.4.3; the
R Foundation for Statistical Computing, Vienna, Austria). The dose–
volume indices (DVIs) were compared between BM and OM using
the paired t‐test, and a P < 0.05 was considered to indicate statisti-
cal significance.
3 | RESULTS
In the simulation plans, 2 of the 10 patients required minor devia-
tions in the PTV D95% due to OARs close to the PTV and difficulty
to comply the dose constraints; however, the other dose–volume
constraints were all met. The DVIs of the simulation plans and
assigned plans are shown in Figs. 2 and 3.
The positional differences (mean ± standard deviation [SD])
between BM and OM were 1.4 ± 2.3 (range, −3.1 to 5.8), 0.4 ± 1.7
(range, −3.2 to 4.4) and −0.2 ± 3.6 (range, −7.2 to 10.6) mm in the
lateral, vertical, and longitudinal directions, respectively. Positive val-
ues indicate that OM showed more couch movement to the left,
posterior, and superior directions than did BM. Differences of the
water equivalent path length (WEPL) at isocenter from simulation
plans (mean ± SD) in 140°, 180°, 220° and 270° fields were
F I G . 5 . Differences in the DVIs of the
target volumes between bone matching
(BM) and organ matching (OM). The
horizontal and vertical axes show the
differences obtained using BM and OM,
respectively. The four symbol shapes
indicate the plan type (circle: RP plan,
square: RPOL plan, rhombus: ORPOL plan,
triangle: VMAT plan), and the 10 colors the
10 patients. The chain line is the line at
which the dose difference using BM versus
OM is the same.
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0.5 ± 1.4 (range, −2.0 to 3.0), 0.9 ± 1.8 (range, −2.0 to 4.0), 0.2 ± 1.6
(range, −4.0 to 4.0) and −2.3 ± 5.1 (range, −15.0 to 8.0) mm with BM,
and −0.7 ± 2.5 (range, −6.0 to 4.0), 0.2 ± 2.8 (range, −8.0 to 6.0), 0.2 ±
2.7 (range, −7.0 to 5.0) and −0.4 ± 5.2 (range, −13.0 to 9.0) mm,
respectively (Fig. 4). Positive values indicate that the WEPL increased
in assigned plans. These values show that the 270° field had more
deviation than other fields; particularly, student’s t‐test showed that
there were significant differences with BM (P < 0.05).
The differences (mean ± 2 SD) in the DVIs between the simula-
tion and assigned plans are shown in Table 2. Figure 5 shows the
differences in the D50% and D98% of the GTV and GTV + 5 mm
using OM vs BM. The differences in both GTV and GTV + 5 mm
D50% were within ±1% on average in all IMPT and VMAT plans for
both setup correction methods. However, those of D98% varied
between the plans, ranging from −0.8% to −5.9% on average. The
tendency of a larger deviation from zero of the mean differences in
F I G . 6 . Cumulative frequency of dose–volume differences in organs at risk between assigned and simulation plans. The four symbol shapes
show the plan type (circle: RP plan, square: RPOL plan, rhombus: ORPOL plan, triangle: VMAT plan). The red dashed versus blue solid lines
show the data obtained using bone matching versus organ matching, respectively. The dotted line shows no change in dose–volume indices in
the horizontal axis and 50% change in the vertical axis.
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the GTV and GTV+5 mm D98% was greater in the RP and RPOL
plans than in the ORPOL and VMAT plans. In addition, the two SD
values of the differences were >10% in the RP and RPOL plans,
even for GTV D98%. Comparing BM and OM, the difference in the
GTV D98% was significantly improved with OM in the VMAT plan,
and that of the GTV+5 mm D98% was improved in the RPOL,
ORPOL, and VMAT plans (P < 0.05).
Regarding the OARs, the VMAT plan caused larger interfractional
variations in the stomach V45Gy and V48Gy than did the three IMPT
plans. No notable differences in the DVIs in the duodenum or small
intestine were observed among the plans. Although the average dif-
ference in the DVI in the duodenum was within ±1 cm3 for BM and
OM, the DVIs were significantly improved by OM on all plans
(P < 0.01). Graphs of the cumulative frequencies showing the differ-
ences in the V45Gy, V48Gy, and V52Gy of the stomach, duodenum, and
small intestine are shown in Fig. 6. While the graphs should ideally
be in the shape of a step (as planned) or show a shift to the negative
side (better in the assigned plans), the graphs tended to deviate
more with BM than with OM.
4 | DISCUSSION
To the best of our knowledge, this is the first report to investigate
the impact of setup correction methods on interfractional dose varia-
tion among multiple IMPT and VMAT plans in pancreatic cancer
patients under EBH conditions. We found that DVIs of assigned
plans for pancreatic cancer tended to improve more with OM than
with BM, except in some cases. Compared with the simulation plan,
the GTV+5 mm D98% was reduced in the assigned plans, but the
magnitude was significantly smaller with OM than with BM on the
RPOL, ORPOL and VMAT plans. This indicates that OM may be use-
ful not only for photon therapy but also for PBT with selected beam
paths. The duodenum also showed significant DVI differences
between BM and OM on all plans, in contrast to only small DVI dif-
ferences between the IMPT and VMAT plans. The duodenum is a
radiosensitive organ, and toxicity in the duodenum has been
reported during treatment of pancreatic cancer; this significant dose
reduction with OM is useful to reduce toxicity. Meanwhile, the
stomach and small intestine showed no significant differences
F I G . 7 . Change in dose distribution.
Comparison of the dose distribution
between the original plan (left) and the
plan assigned to the first additional CT
(right) in (a) RP, (b) RPOL, (c) ORPOL and
(d) VMAT plans.
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between BM and OM. Bowel gas and gastrointestinal contents vary
with time,9,18 and changes in the stomach and small intestine shapes
due to these variations lead to both increases and decreases in the
DVIs for each CT set.
As expected, positional differences were different between BM
and OM, especially in the longitudinal direction. The SD values indi-
cated that extreme deviations sometimes occurred, and 3 of 30 addi-
tional CT sets showed differences of >5 mm. These deviations were
considered to derive from EBH failure.6 Pancreatic cancer showed
systematic deviation in the lateral direction. From this finding, the
target dose was considered better with OM compared with BM;
however, this did not apply to all plans. Positional differences
between the tumor and bony anatomy may result in both source‐to‐
surface distance variations and variations in anatomical structures on
beam paths. Proton dose distributions are not appreciably affected
by source‐to‐surface distance but are affected by perpendicular
shifts in the beam direction and by anatomical variations.21 Organ‐
matching could reduce the perpendicular shifts of targets and OARs
owing to more precise position repeatability against breath‐hold
position deviations. And for anatomical variations, a high robustness
of VMAT for interfractional anatomical changes and considerable
deviations between the planned and accumulated doses in PBT has
been reported in pancreatic cancer patients.14 This supported our
finding that the interfractional dose differences in the GTV+5 mm
D98% were approximately 50% or less in the VMAT plan, compared
with all proton plans using BM and OM (Table 2). As notable exam-
ples of dose distribution distortion, a decrease of more than 20% in
the GTV+5 mm D98% was observed in all plans using BM for some
patients. The representative dose distributions for one of these
patients are shown in Fig. 7. In this case, the dose–volume
F I G . 8 . A notable example of the effect of beamlet intensity on the RP plan. The RP plan had a worse dose distribution with OM than with
BM. (a): The target beamlet position on the intensity weight map (arrowed position). (b)–(d): Axial and coronal planes of the target beamlet
path on the simulation plan, the assigned plan with BM and that with OM, respectively. The white lines indicate the target beamlet path line
and the crosses show the additional points the water equivalent path length measured in this notable patient, 17 mm left, 10 mm anterior, and
2.5 mm inferior from isocenter.
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constraints were all met in each plan; however, GTV+5 mm D98%
greatly decreased in all assigned plans with BM and in assigned
IMPT plans with OM. When comparing the simulation CT set and
additional CT sets of this patient, in addition to tumor movement to
the left side, the gastrointestinal gas on the simulation CT decreased
somewhat on the additional CTs. It has been reported that one of
the largest interfractional anatomical deviations in pancreatic cancer
patients is the change in the gastrointestinal gas volume.13 The
effect of changes in the gastrointestinal gas volume on dose distribu-
tion has been reported for CIRT over the duration of one fraction,
and a reduction in target coverage was demonstrated. Kumagai et al.
have reported that the distortion of the dose distribution due to gas-
trointestinal gas volume variations appeared mainly on the beam
from the anterior and left side of the patients;18 however, distortion
of the dose distribution was also observed on the beam from the
right side in our study. Abdominal organs other than the gastroin-
testinal tract showed little deviation in electron density; however,
gastrointestinal gas can reduce the WEPL greatly. In the cases with
worse DVIs in the RP and RPOL plans using OM than BM, gastroin-
testinal gas surrounded the tumor on the simulation CT but little gas
was present on the assigned CT set (Fig. 8). In this patient, the
WEPL difference from simulation plan at additional point on high‐in-
tensity beamlet of 270° field was quite deviated than mean differ-
ence of 10 patients at isocenter and larger with OM (30 mm) than
BM (21 mm). A large WEPL change with both BM and OM could be
avoided using the ORPOL plan owing to less gastrointestinal gas on
beam paths. Thus, the gastrointestinal gas has a considerable effect
on the dose distribution, and it is difficult to predict the location of
gastrointestinal gas during the course of treatment. If in the simula-
tion plan the CT numbers of the gastrointestinal gas were overridden
to match those of the surrounding tissue, a shorter WEPL due to
gastrointestinal gas could lead to an overdose in OARs at actual irra-
diation.
Changes in body habitus over the treatment course would also
result in a change in the WEPL; therefore, replanning in IMPT
patients will allow adjustments due to these changes. However,
changes in WEPL due to gastrointestinal gas are difficult to evaluate,
particularly using the BM method, including the use of orthogonal
kV x‐ray images. Thus, an OM such as CBCT is considered prefer-
able to evaluate WEPL during actual irradiation.
In this study, EBH was used for respiratory motion management
because it provides a high interfractional reproducibility of the pancre-
atic tumor position.6 While in all IMPT and VMAT plans under EBH
irradiation more than one breath‐hold will be necessary, a high
intrafractional reproducibility of the pancreatic tumor position under
multiple EBH using RPM has been reported.8 Therefore, the intrafrac-
tional dose variation derived from multiple EBH was considered to be
smaller than that resulting from setup correction methods.
There were several limitations to this study. First, only ten
patients were evaluated. However, even with this small number of
cases, significant differences in DVIs between the simulation and
assigned IMPT plans could be determined. Additionally, these differ-
ences were dependent on the setup correction method. Second, we
did not use deformable image registration (DIR) to evaluate dose
accumulation but evaluated the dose distribution at certain time
points. However, registration uncertainties in DIR result in inaccurate
deformed delineations and dose distributions,22 and there are advan-
tages to using additional CT instead of daily CBCT to reduce delin-
eation uncertainties, due to the poor soft‐tissue contrast on CBCT
images. Third, we did not use robust optimization in the IMPT plans,
which is suggested to protect against positional errors and range
uncertainty by optimizing the sharp dose fall off to OARs.21 How-
ever, we did address positional error via setup correction methods.
As mentioned above, the dose distribution tended to be better with
OM compared with BM; therefore, the positional error was
addressed effectively. However, in some cases, residual distortion of
the dose distribution with OM was noted, particularly on the RP and
RPOL plans. Moreover, the dose distributions using OM were even
worse. The proposed robustness of IMPT is not achievable with
positional repeatability alone. In the case of range uncertainty, the
WEPL changes readily and significantly with interfractional anatomi-
cal variations such as gastrointestinal gas as shown in Fig. 6, and it is
doubtful whether the robust optimization results were superior with
VMAT plans compared with IMPT plans.
5 | CONCLUSION
Organ‐matching may be a better setup correction technique than
BM for both photon therapy and IMPT plans. However, in some
beam arrangements of IMPT, the dose distribution may be some-
what worse using OM due to interfractional anatomical variation.
Therefore, it is important to choose beam angles that are less likely
to be influenced by changes in gastrointestinal gas volume, especially
when IMPT plans are used.
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